MedPath

DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study

Not Applicable
Completed
Conditions
Uncontrolled Hypertension
Interventions
Device: Renal denervation
Registration Number
NCT04248530
Lead Sponsor
Kalos Medical
Brief Summary

The study is the multicenter pilot study to obtain an assessment of the safety of renal denervation in the patients with uncontrolled hypertension on standard medical therapy in Korea.

Detailed Description

DENEX system developed by Handok Kalos Medical Inc. is a renal nerve blocking system to efficiently block the sympathetic nerve of the kidney with minimal invasive procedure. It was developed to block the sympathetic nerves distributed in blood vessel wall by delivering high frequency energy to the renal artery for the purpose of treating hypertension.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria
  1. Individual is ≥ 20 years of age at time of consent
  2. Individual has office systolic blood pressure (SBP) of ≥ 150 mmHg
  3. Individual has daytime 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP of ≥ 140 mmHg
  4. Individual maintains the following 3 antihypertensive medications: thiazide-type diuretic, calcium-channel blocker, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (for at least 6 weeks before the screening visit) that is expected to be maintained without changes for at least 6 months.
Exclusion Criteria
  1. Main renal artery contains renal artery stenosis >50%
  2. Individual has confirmed anatomical findings in kidneys or renal arteries through CT scan or angiogram
  3. Undergone prior renal angioplasty
  4. Main renal arterial vessel for each kidney <4 and >8 mm in diameter, or <20 mm length
  5. Individual has an Estimated glomerular filtration rate <45 mL/min/1.73 m2 at screening visit
  6. Individual has experienced myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 3 months of the screening period, or has widespread atherosclerosis, with documented intravascular thrombosis or unstable plaques
  7. Individual has Hemodynamically or echocardiography significant valvular heart disease
  8. Individual has secondary hypertension (pheochromocytoma, Cushing syndrome,coarctation of the aorta, renovascular hypertension, primary hyperaldosteronism, or other secondary hypertension)
  9. Individual has documented primary pulmonary hypertension
  10. Individual has orthostatic hypotension with symptom
  11. Individual requires chronic oxygen support for sleep apnea
  12. Individual is taking chronic NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Only, Aspirin is permitted for cardiovascular disease prevention
  13. Individual has Type 1 diabetes mellitus

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Renal denervation therapy groupRenal denervationThe subject treated by renal denervation by using DENEX system.
Primary Outcome Measures
NameTimeMethod
Rate of all adverse eventsFrom baseline to 1 month post-procedure

rate of major adverse events for 1 month after the treatment

Secondary Outcome Measures
NameTimeMethod
Percentage of decreased office SBP >10, 15, 20 mmHgFrom baseline to 1, 3, 6, 12, 18, 24 months post-procedure

Percentage of subjects decreased office systolic blood pressure \> 10 mmHg, 15 mmHg, 20 mmHg at 1, 3, 6, 12, 18, 24 months post denervation

Office SBP change at 1, 3, 6, 12, 18, 24 monthsFrom baseline to 1, 3, 6, 12, 18, 24 months post-procedure

Change in office systolic blood pressure at 1, 3, 6, 12, 18, 24 months post denervation

Ambulatory SBP change at 3,6,12,24 monthsFrom baseline to 3, 6, 12, 24 months post-procedure

Change in systolic blood pressure as measured by 24-hour ABPM at 3, 6, 12, 24 months post denervation

Trial Locations

Locations (5)

Pusan National University Hospital

🇰🇷

Pusan, Korea, Republic of

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

Korea University Guro Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul St.Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

Uijeongbu St. Mary's Hospital

🇰🇷

Uijeongbu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath